Table of contents
March 2006 Volume 3 No 3
Editorial
Viewpoint
The male perineal sling—a viable alternative to the artificial urinary sphincter
118This Viewpoint provides a timely review of the current status of surgical treatments for men who develop stress urinary incontinence after radical prostatectomy. The author discusses the safety and efficacy of the bone-anchored perineal sling, a procedure that has recently undergone several modifications and is arguably emerging as a viable alternative to the artificial urinary sphincter.
Research Highlights
Vitamin D analog BXL628 arrests prostate growth in patients with benign prostatic hyperplasia
120Smoking could influence prostate cancer progression via gene hypermethylation
120Upper urinary tract surveillance in patients with stage Ta bladder cancer
120Sperm retrieval in patients with Klinefelter's syndrome
121Better outcomes for patients with intermediate-risk and poor-risk metastatic germ-cell tumors
121Post-TURP stricture could be prevented by COX2 inhibitor therapy
122Ixabepilone shows activity in hormone-refractory prostate cancer
123Endoscopic treatment of vesicoureteral reflux is safe but not highly effective
123BCG plus mitomycin is more effective than BCG alone in bladder cancer
123Urethral function assessment without catheterization
124Beneficial effect of statins in patients with prostate cancer
124Practice Points
Can androgen deprivation be considered a primary treatment for prostate cancer?
126Botulinum toxin for overactive bladder: reaching a happy median
128Conservative surgery for penile cancer: what surgical excision margins are needed to achieve oncologic control?
132Are men with testicular cancer at risk of developing a contralateral tumor?
134Reviews
Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
138Neuroendocrine cancer of the prostate is a challenging disease to characterize and treat. Although there are a number of diagnostic and prognostic markers for this disease, no definitive marker exists. In this Review, the characterization of neuroendocrine differentiation and the management of patients with these tumors of the prostate are discussed.
doi:10.1038/ncpuro0435 | Full Text | PDF (142K)
Traditional therapy for chronic pelvic pain does not work: what do we do now?
145Chronic pelvic pain syndromes are notoriously difficult to manage; little is known about their pathophysiology and most treatments are aimed at relieving the pain associated with the different disorders. This Review discusses some of the available treatments that are being used for the management of chronic pelvic pain and novel therapies that are under investigation.
doi:10.1038/ncpuro0438 | Full Text | PDF (198K)
Mechanisms of Disease: angiogenesis in urologic malignancies
157A number of angiogenic pathways have been implicated in urologic cancers, which could hold the key to developing antiangiogenic therapies against such tumors. Promoters and inhibitors of angiogenesis in tumors of the prostate, bladder and kidneys, and their use as either tumor markers or potential anticancer treatments, are reviewed in this article.
doi:10.1038/ncpuro0434 | Full Text | PDF (224K)
